A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status.

Trial Profile

A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs Panitumumab (Primary) ; Carboplatin; Vinorelbine; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms Lung-TRIO
  • Most Recent Events

    • 13 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Apr 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 30 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top